TY - JOUR
T1 - Effect of Cimetidine on Survival after gastric cancer
AU - Tonnesen, Hanne
AU - Bülow, Steffen
AU - Fischerman, Kaj
AU - Hjortrup, Allan
AU - Møller Pedersen, Vilhelm
AU - Bo Svendsen, Lars
AU - Knigge, Ulrich
AU - Damm, Peter
AU - Hesselfeldt, Peter
AU - Krogh Pedersen, Ib
AU - Julius Siemssen, Ole
AU - Martin Christiansen, Poul
PY - 1988/10/29
Y1 - 1988/10/29
N2 - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.
AB - The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.
U2 - 10.1016/S0140-6736(88)90743-X
DO - 10.1016/S0140-6736(88)90743-X
M3 - Article
C2 - 2902494
AN - SCOPUS:0023816023
SN - 0140-6736
VL - 332
SP - 990
EP - 992
JO - The Lancet
JF - The Lancet
IS - 8618
ER -
